Risk of alveolar hemorrhage in patients with primary pulmonary hypertension: Anticoagulation and epoprostenol therapy

Circulation Journal

Volumn 69, Issue 2, 2005, Pages 216-220

  Ogawa, Aiko ^a   Matsubara, Hiromi ^b   Fujio, Hideki ^a   Miyaji, Katsumasa ^a   Nakamura, Kazufumi ^a   Morita, Hiroshi ^a   Saito, Hironori ^a   Kusano, Kengo Fukushima ^a   Emori, Tetsuro ^a   Date, Hiroshi ^a   Ohe, Tohru ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Alveolar hemorrhage; Anticoagulation; Epoprostenol; Primary pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HUMAN; LUNG HEMORRHAGE; MALE; MEDICAL RECORD; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; FEMALE; HEMORRHAGE; HUMANS; HYPERTENSION, PULMONARY; MALE; PLATELET AGGREGATION INHIBITORS; PULMONARY ALVEOLI; RETROSPECTIVE STUDIES; RISK;

EID: 20044395254     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.216     Document Type: Article

References (17)

1. Sugiyama S, Hirota H, Yoshida M, Takemura Y, Nakaoka Y, Oshima Y, et al. Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension. Circ J 2002; 68: 592-594.
2. Hashimoto K, Nakamura K, Fujio F, Miyaji K, Morita H, Kusano K, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J 2004; 68: 227-231.
3. Kusano FK, Date H, Fujio H, Miyaji K, Matsubara H, Nagahiro I, et al. Recovery of cardiac function after living-donor lung transplantation in a patient with primary pulmonary hypertension. Circ J 2002; 66: 294-296.
4. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
6. Whittle BJR, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 1978; 16: 373-388.
7. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
8. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
9. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
10. Yuceoglu YZ, Dresdale DT, Valensi QJ, Narvas RM, Gottlieb NT. Primary pulmonary hypertension with hoarseness and massive (fatal) hemoptysis: Review of the literature and report of a case. Vasc Dis 1967; 4: 290-304.
11. Dresdale DT, Schults M, Michtom RJ. Primary pulmonary hypertension. I: Clinical and hemodynamic study. Am J Med 1951; 11: 686-705.
12. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987; 107: 216-223.
13. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112: 714-721.
14. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 35S-62S.
15. Boyer-Neumann C, Brenot F, Wolf M, Peynaud-Debayle E, Duroux P, Meyer D, et al. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thromb Haemost 1995; 73: 735-736.
16. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-2784.
17. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial (Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group). Stroke 2000; 31: 817-821.